These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32072673)

  • 1. Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach.
    Grosse A; Grosse C
    Cytopathology; 2020 May; 31(3):232-235. PubMed ID: 32072673
    [No Abstract]   [Full Text] [Related]  

  • 2. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
    Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
    Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon.
    El Hussein S; Khader SN
    Diagn Cytopathol; 2019 Aug; 47(8):845-850. PubMed ID: 31017747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.
    Chen HF; Wang WX; Li XL; Xu CW; Du KQ; Zhu YC; Fang MY
    J Thorac Oncol; 2019 Oct; 14(10):e217-e219. PubMed ID: 31558230
    [No Abstract]   [Full Text] [Related]  

  • 5. Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.
    Zaemes J; Hall RD; Gentzler RD
    J Thorac Oncol; 2018 Aug; 13(8):e136-e137. PubMed ID: 30049373
    [No Abstract]   [Full Text] [Related]  

  • 6. Pseudoprogression and Rapid Response to Pembrolizumab in a Patient with Advanced Lung Adenocarcinoma with Loss of Epidermal Growth Factor Receptor Gene Mutation after Tyrosine Kinase Inhibitor Therapy.
    Yamaura T; Suzuki H
    J Thorac Oncol; 2018 Oct; 13(10):e209-e210. PubMed ID: 30244857
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.
    Hakozaki T; Kitazono M; Takamori M; Kiriu T
    Intern Med; 2020 May; 59(10):1291-1294. PubMed ID: 32101830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
    Li S; Zhao J; Wang Q
    J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
    Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Squamous Transition of Lung Adenocarcinoma and Drug Resistance.
    Hou S; Han X; Ji H
    Trends Cancer; 2016 Sep; 2(9):463-466. PubMed ID: 28741476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
    Reale ML; Chiari R; Tiseo M; Vitiello F; Barbieri F; Cortinovis D; Ceresoli GL; Finocchiaro G; Romano GD; Piovano PL; Del Conte A; Borra G; Verderame F; Scotti V; Nonnis D; Galetta D; Sergi C; Migliorino MR; Tonini G; Cecere F; Berardi R; Pino MS; Martelli O; Gelibter A; Carta A; Vattemi E; Pagano M; Zullo A; Ferrari S; Rossi A; Novello S
    Lung Cancer; 2020 Feb; 140():71-79. PubMed ID: 31884129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Yang JC; Yu CJ
    Eur J Cancer; 2019 Aug; 117():107-115. PubMed ID: 31279301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors.
    Zhou Z; Zhao Y; Shen S; Gu L; Niu X; Xu Y; Zhang T; Xiang J; Mao X; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):e157-e159. PubMed ID: 31075545
    [No Abstract]   [Full Text] [Related]  

  • 15. Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
    Wang F; Qin J; Xie F; Wu Q; Lu H
    Lung Cancer; 2020 Feb; 140():118-120. PubMed ID: 31924369
    [No Abstract]   [Full Text] [Related]  

  • 16. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
    Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
    Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
    Bergqvist M; Christensen HN; Wiklund F; Bergström S
    Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].
    Moldvay J; Peták I
    Magy Onkol; 2012 Mar; 56(1):38-49. PubMed ID: 22403761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
    BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
    Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
    Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.